06/12/2001
London, UK – 6 December 2001: ReGen Therapeutics Plc (the “Company”), a company developing a potential treatment for Alzheimer’s disease, announces that it has today issued 2,500,000 new ordinary shares to certain of its existing shareholders at 10p per share (“New Ordinary Shares”). The issue of the New Ordinary Shares has been made pursuant to the existing general authority given to Directors at the Extraordinary General Meeting of the Company held on 5 November 2001.
Application has been made for the New Ordinary Shares to be admitted to the Alternative Investment Market of the London Stock Exchange plc and dealings are expected to commence at 8.00 am on 12 December 2001.
Percy Lomax, Chairman, commented, “Following the successful fundraisings completed by the Company in November 2001, we are pleased to have received additional demand from our shareholders at this time confirming, we believe, their confidence in the Company.”
For further information, please contact:
Lisa Baderoon
BUCHANAN COMMUNICATIONS
Tel No: 020 7466 5000
lisab@buchanan.uk.com
M: 07721 413496